Senseonics Holdings, Inc. (NYSE:SENS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have received a consensus recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $22.70.

Several brokerages have recently commented on SENS. Stifel Nicolaus began coverage on Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 price objective for the company. Barclays reiterated an “overweight” rating and set a $31.00 price target (up previously from $1.50) on shares of Senseonics in a report on Wednesday, November 5th. TD Cowen restated a “buy” rating on shares of Senseonics in a research note on Thursday, January 8th. Finally, HC Wainwright lifted their price objective on shares of Senseonics to $18.50 and gave the stock a “buy” rating in a report on Thursday, November 6th.

Insiders Place Their Bets

In other news, Director Edelman Steven acquired 10,000 shares of Senseonics stock in a transaction on Monday, November 10th. The stock was acquired at an average cost of $6.55 per share, with a total value of $65,500.00. Following the transaction, the director owned 74,708 shares of the company’s stock, valued at approximately $489,337.40. This trade represents a 15.45% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Frederick T. Sullivan bought 5,415 shares of the company’s stock in a transaction on Friday, November 7th. The shares were purchased at an average cost of $5.88 per share, for a total transaction of $31,840.20. Following the transaction, the chief financial officer owned 157,028 shares in the company, valued at approximately $923,324.64. This represents a 3.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 30,415 shares of company stock valued at $184,790. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SENS. First Light Asset Management LLC raised its stake in shares of Senseonics by 666.7% during the 2nd quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock worth $17,011,000 after purchasing an additional 31,050,619 shares during the period. Vanguard Group Inc. increased its holdings in Senseonics by 2.2% during the third quarter. Vanguard Group Inc. now owns 34,219,484 shares of the company’s stock worth $14,920,000 after buying an additional 749,453 shares during the last quarter. Geode Capital Management LLC raised its position in Senseonics by 26.6% in the second quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock worth $4,147,000 after acquiring an additional 1,828,302 shares during the period. Hood River Capital Management LLC bought a new stake in Senseonics in the second quarter worth about $3,775,000. Finally, Masters Capital Management LLC boosted its stake in Senseonics by 11.1% in the third quarter. Masters Capital Management LLC now owns 5,000,000 shares of the company’s stock valued at $2,179,000 after acquiring an additional 500,000 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Trading Down 2.7%

NYSE:SENS opened at $7.31 on Friday. Senseonics has a one year low of $5.25 and a one year high of $28.00. The company has a market cap of $298.68 million, a PE ratio of -56.23 and a beta of 0.63. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm has a 50-day moving average of $6.43 and a 200-day moving average of $8.08.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.